Search Results
Feb 16, 2026, 16:40 ET Wheaton Precious Metals Announces Acquisition of Additional Silver Stream on Antamina Through New Partnership with BHP
Capitalization calculated as of February 13, 20263 Based on 2026 commodity price assumptions of $4,800/oz Au, $80/oz Ag, $1,500/oz Pd, $2,000/oz Pt, and $25/lb Co.4 Company reports S&P Global estimates of 2025 byproduct cost curves for gold, zinc/lead, copper,
More news about: Wheaton Precious Metals Corp.
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
doi:10.1200/JCO.2024.42.16_suppl.TPS811Huang RSP, et al. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathol Oncol Res. 2021;27:592997. Published 2021 Mar 11. doi:10.3389/pore.2021.592997Wang R, Hu H, Pan Y, et al. RET fusions
More news about: Eli Lilly and Company
Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
progresses."About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)CS2009, an innovative trispecific antibody designed and developed by CStone, with the potential to be first- or best-in-class. It combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional
More news about: CStone Pharmaceuticals
Feb 13, 2026, 11:03 ET El mejor estilo se une a la potencia de vanguardia en la nueva generación Highlander 2027 de Toyota
capacidades de detección y cuentan con las siguientes características: Sistema de precolisión con detección de peatones (PCS con PD): está diseñado para ayudar a detectar un vehículo, peatón, ciclista o motociclista y dar una advertencia de colisión frontal sonora o visual en determinadas
More news about: Toyota Motor North America
Feb 13, 2026, 06:08 ET STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit www.bio-thera.com/en/
More news about: Bio-Thera Solutions, Ltd
Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs
More news about: HanchorBio Inc.
Feb 12, 2026, 16:15 ET Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.Technology Development:Under a Material Transfer Agreement (MTA), Stavro is evaluating the compatibility
More news about: Aethlon Medical, Inc.
Feb 12, 2026, 07:00 ET Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.
More news about: Compugen Ltd.
Feb 11, 2026, 10:31 ET Kidney Dialysis Market to Reach $149.7 billion, Globally, by 2033 at 6.5% CAGR: Allied Market Research
market players to showcase the competitive scenario. In April 2022, the U.S. Food and Drug Administration (FDA) awarded 510 (k) clearance to the Versi PD Cycler System, a next generation portable automated peritoneal dialysis (APD) system from Fresenius Medical Care North America (FMCNA). VersiPD is the
More news about: Allied Market Research
Feb 11, 2026, 09:10 ET Dr. Emil Lou, Intima Bioscience Principal Investigator, Named to 2026 TIME100 Health List
PLC-γ1, a proximal mediator of TCR complex signaling. Inhibition of CISH in T cells is believed to help overcome immune evasion regardless of tumor type or PD-L1 expression.About Intima BioscienceIntima Bioscience is a clinical stage oncology company focused on curative intent in solid
More news about: Intima Bioscience
Feb 11, 2026, 09:00 ET JSAUX Debuts the Double-Decker Travel Supply Case to Eliminate Battery Anxiety for Steam Deck Owners
Deck and is also compatible with devices like the ROG Ally and Legion Go. It enables a high-performance desktop setup with 4K@60Hz video output and 100W PD fast charging. The integrated stand features bottom vents to maximize airflow and maintain optimal temperatures during extended use.AvailabilityThe
More news about: JSAUX
Feb 10, 2026, 21:30 ET Elevated Style Meets Modern Power in the Next Generation 2027 Toyota Highlander
its hardware and detection capabilities and has the following features: Pre-Collision System with Pedestrian Detection (PCS w/PD) is designed to help detect a vehicle, pedestrian, bicyclist or motorcyclist and provide an audio/visual forward-collision warning under certain circumstances.
More news about: Toyota Motor North America
Feb 10, 2026, 15:29 ET Gentex Corporation, Under Its Ops-Core® Brand, Announces Sponsorship of the Alliance Police Training Facility
seeking advanced training, making it a natural partner for Gentex's commitment to supporting officers where real-world training happens."Alliance PD Range plays a crucial role in preparing law enforcement officers for real-world challenges," said Fred Grimm, VP of Commercial Sales Americas. "We're
More news about: Gentex Corporation
Feb 10, 2026, 08:00 ET Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for the treatment of cancers. The subject claims have been successfully granted in other countries. Should the patent grant, it will strengthen
More news about: Genprex, Inc.
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
oxidative stress, and aging-related neuronal dysfunction—key biological processes underlying the progression of Alzheimer's and Parkinson's diseases (PD). Disruption of these pathways is increasingly recognized as central to neurodegeneration.Based on these results, MerryLife is preparing to initiate
More news about: Merry Life Biomedical Company, Ltd.
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
oxidative stress, and aging-related neuronal dysfunction—key biological processes underlying the progression of Alzheimer's and Parkinson's diseases (PD). Disruption of these pathways is increasingly recognized as central to neurodegeneration.Based on these results, MerryLife is preparing to initiate
More news about: Merry Life Biomedical Company, Ltd.
Feb 09, 2026, 09:00 ET Published Study Found Underlying Tremor Improvement with Consistent use of Cala TAPS Therapy in Patients with Essential Tremor
Local Coverage Criteria. Cala continues to advocate on behalf of patients with ET and PD to secure additional coverage and reimbursement in Medicare Advantage and commercial payor plans. About Cala® Cala Health is a bioelectronic
More news about: Cala Health
Feb 06, 2026, 08:00 ET Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.In addition to advancing its internal pipeline, Insilico Medicine and its global partners have
More news about: Insilico Medicine
Feb 05, 2026, 21:26 ET Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration
More news about: Akeso, Inc.
Feb 05, 2026, 19:36 ET Eisai und Henlius schließen exklusive Lizenzvereinbarung für den Anti-PD-1-Antikörper Serplulimab in Japan ab
Vermarktungs- und Co-Exklusivlizenzvereinbarung für den Anti-PD-1-Antikörper Serplulimab (generischer Name, in der EU unter dem Markennamen Hetronifly® vertrieben) in Japan bekannt. Serplulimab ist ein neuartiger monoklonaler Anti-PD-1-Antikörper, der von Henlius entwickelt wurde und Berichten zufolge
More news about: Henlius
Feb 05, 2026, 19:36 ET Eisai et Henlius concluent un accord de licence commerciale exclusive pour l'anticorps anti-PD-1 serplulimab au Japon
pour l'anticorps anti-PD-1 serplulimab (nom générique ; commercialisé sous le nom de Hetronifly® dans l'UE) au Japon. Le serplulimab est un nouvel anticorps monoclonal anti-PD-1 développé par Henlius et dont le mode de liaison est unique et différent des anticorps anti-PD-1 existants. En Chine,
More news about: Henlius
Feb 05, 2026, 09:13 ET Eisai y Henlius firman un acuerdo comercial para el anticuerpo anti-PD-1 serplulimab en Japón
para el anticuerpo anti-PD-1 serplulimab (nombre genérico; comercializado como Hetronifly® en la UE) en Japón. Serplulimab es un nuevo anticuerpo monoclonal anti-PD-1 desarrollado por Henlius, que presenta un mecanismo de unión único, distinto al de los anticuerpos anti-PD-1 existentes. En China,
More news about: Henlius
Feb 05, 2026, 08:00 ET Empyrean Solutions Launches Model IQ™, a Next-Generation Behavioral Modeling Solution for Financial Institutions
Credit loss and recovery assumption modeling using peer data or institution-specific history, supporting both net charge-off, cohort loss rates, and PD/LGD methodologies.Purpose-built for community and regional financial institutions, Model IQ enables teams to respond to market changes in
More news about: Empyrean Solutions
Feb 05, 2026, 06:56 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
license agreement for the anti-PD-1 antibody serplulimab (generic name; marketed as Hetronifly® in the EU) in Japan. Serplulimab is a novel anti-PD-1 monoclonal antibody developed by Henlius and reported to have a unique binding mode distinct from existing anti-PD-1 antibodies. In China, it has
More news about: Henlius
Feb 05, 2026, 06:44 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan. Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies.[1] In
More news about: Henlius